From: CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study
Variables | Patients (N= 645) |
---|---|
Females | 484 (75.0) |
Median patient age at time of disease diagnosis, years (IQR) | 56 (45 to 65) |
Median follow-up, years (IQR) | 13 (7 to 19) |
Anti-CCP-positive (N = 470) | 283 (60.2) |
Rheumatoid factor-positive (N = 635) | 474 (74.7) |
Shared epitope (N = 579) | 366 (63.2) |
Cardiovascular events | 87 (13.5) |
Ischemic heart disease | 47 (7.3) |
Cerebrovascular accidents | 19 (2.9) |
Heart failure | 23 (3.6) |
Peripheral arteriopathy | 10 (1.6) |
Hypertension (N = 640) | 248 (38.8) |
Diabetes mellitus (N = 637) | 74 (11.6) |
Dyslipidemia (N = 621) | 282 (45.4) |
Obesity (N = 610) | 66 (10.8) |
Smoking habit (N = 621) | 112 (18.0) |
CCR5Δ32 rs333 | |
CCR5/CCR5 | 579 (89.8) |
CCR5 /CCR5Δ32 | 64 (9.9) |
CCR5Δ32 /CCR5Δ32 | 2 (0.3) |
CCR5 | 1,222 (94.7) |
CCR5Δ32 | 68 (5.3) |